Ferozsons Laboratories Ltd.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: PK0005201014
PKR
379.11
22.81 (6.4%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 12.26

 
2

Healthy long term growth as Operating profit has grown by an annual rate 35.27%

 
3

Positive results in Mar 25

4

With ROE of 7.1, it has a attractive valuation with a 1.3 Price to Book Value

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

PKR 16,260 Million (Small Cap)

stock-summary
P/E

20.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

1.07%

stock-summary
Debt Equity

0.10

stock-summary
Return on Equity

7.94%

stock-summary
Price to Book

1.29

Revenue and Profits:
Net Sales:
5,092 Million
(Quarterly Results - Mar 2025)
Net Profit:
248 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
16.05%
0%
16.05%
6 Months
3.22%
0%
3.22%
1 Year
57.28%
0%
57.28%
2 Years
167.83%
0%
167.83%
3 Years
71.53%
0%
71.53%
4 Years
23.36%
0%
23.36%
5 Years
61.22%
0%
61.22%

Ferozsons Laboratories Ltd. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
25.99%
EBIT Growth (5y)
26.55%
EBIT to Interest (avg)
12.26
Debt to EBITDA (avg)
0.80
Net Debt to Equity (avg)
0.18
Sales to Capital Employed (avg)
1.08
Tax Ratio
34.23%
Dividend Payout Ratio
22.39%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
16.80%
ROE (avg)
9.47%
Valuation key factors
Factor
Value
P/E Ratio
20
Industry P/E
Price to Book Value
1.48
EV to EBIT
9.57
EV to EBITDA
6.63
EV to Capital Employed
1.42
EV to Sales
1.07
PEG Ratio
0.90
Dividend Yield
1.66%
ROCE (Latest)
14.83%
ROE (Latest)
7.45%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bearish
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is 7.63% vs 4.46% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is 39.53% vs -26.31% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "5,091.90",
          "val2": "4,731.00",
          "chgp": "7.63%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "756.50",
          "val2": "674.20",
          "chgp": "12.21%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "109.70",
          "val2": "171.50",
          "chgp": "-36.03%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "247.80",
          "val2": "177.60",
          "chgp": "39.53%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "96.00%",
          "val2": "97.20%",
          "chgp": "-0.12%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Jun'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Jun 2024 is 38.38% vs 22.80% in Jun 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Jun 2024 is 155.06% vs -62.50% in Jun 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'24",
        "Jun'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "15,854.80",
          "val2": "11,457.20",
          "chgp": "38.38%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "2,108.00",
          "val2": "1,295.50",
          "chgp": "62.72%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "670.60",
          "val2": "302.50",
          "chgp": "121.69%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "49.70",
          "val2": "5.00",
          "chgp": "894.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "755.50",
          "val2": "296.20",
          "chgp": "155.06%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "99.00%",
          "val2": "71.80%",
          "chgp": "2.72%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQstock-summary
Mar'25
Dec'24
Change(%)
Net Sales
5,091.90
4,731.00
7.63%
Operating Profit (PBDIT) excl Other Income
756.50
674.20
12.21%
Interest
109.70
171.50
-36.03%
Exceptional Items
0.00
0.00
Consolidate Net Profit
247.80
177.60
39.53%
Operating Profit Margin (Excl OI)
96.00%
97.20%
-0.12%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Mar 2025 is 7.63% vs 4.46% in Dec 2024

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Mar 2025 is 39.53% vs -26.31% in Dec 2024

Annual Results Snapshot (Consolidated) - Jun'24stock-summary
Jun'24
Jun'23
Change(%)
Net Sales
15,854.80
11,457.20
38.38%
Operating Profit (PBDIT) excl Other Income
2,108.00
1,295.50
62.72%
Interest
670.60
302.50
121.69%
Exceptional Items
49.70
5.00
894.00%
Consolidate Net Profit
755.50
296.20
155.06%
Operating Profit Margin (Excl OI)
99.00%
71.80%
2.72%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Jun 2024 is 38.38% vs 22.80% in Jun 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Jun 2024 is 155.06% vs -62.50% in Jun 2023

stock-summaryCompany CV
About Ferozsons Laboratories Ltd. stock-summary
stock-summary
Ferozsons Laboratories Ltd.
Pharmaceuticals & Biotechnology
Ferozsons Laboratories Limited is a Pakistan-based holding company, which is primarily engaged in importing, manufacturing and sale of pharmaceuticals products. The Company offers a range of branded generics and in-licensed products in the areas of cardiology, oncology, gastroenterology, dermatology and anti-infective markets in the Pakistan. The Company's production capabilities include the manufacturing of tablets, capsules, syrups, suspensions, creams and ointments. Its products include Salazodine EC Tabs, Cimet Tablets and Suspension, Centaurus Tablets, Novapressin, Filgen Injection, Oxaltie Injection, Imuxgen Tablets, Anfogen Injection and Donataxel Injection, among others. The Company's subsidiaries include BF Biosciences Limited, which is engaged in the import, manufacturing and sale of pharmaceutical products and Farmacia, which is engaged in the sale and distribution of medicines and other related products.
Company Coordinates stock-summary
Company Details
197- A ,The Mall , RAWALPINDI None : 46000
Registrar Details